CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.21.00550 JCO Precision Oncology no. 6 (2022) e2100550. Published online July 12, 2022. PMID: 35820086 CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone Sminu Bose , MD1xSminu BoseSearch for articles by this author; Tristan Lee , MD2xTristan LeeSearch for articles by this author; Shaelyn Choi, BA1xShaelyn ChoiSearch for articles by this author; Ladan Fazlollahi, MD, MPH3xLadan FazlollahiSearch for articles by this author; Michael J. Rasiej , MD4xMichael J. RasiejSearch for articles by this author; Gary K. Schwartz, MD1xGary K. SchwartzSearch for articles by this author; and Matthew Ingham , MD1xMatthew InghamSearch for articles by this author Show More 1Division of Hematology and Medical Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY2Department of Medicine, Columbia University Irving Medical Center, New York, NY3Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY4Department of Radiology, Columbia University Irving Medical Center, New York, NY*S.B., T.L., and S.C. contributed equally to this work. https://doi.org/10.1200/PO.21.00550 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Matthew InghamFinancial support: Matthew InghamAdministrative support: Gary K. Schwartz, Matthew InghamProvision of study materials or patients: Matthew InghamCollection and assembly of data: Sminu Bose, Michael J. Rasiej, Gary K. Schwartz, Matthew InghamData analysis and interpretation: Sminu Bose, Shaelyn Choi, Ladan Fazlollahi, Michael J. Rasiej, Gary K. Schwartz, Matthew InghamManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Gary K. SchwartzStock and Other Ownership Interests: GenCirq, Bionaut Labs, January TherapeuticsConsulting or Advisory Role: Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTechResearch Funding: Astex Pharmaceuticals, Incyte (Inst), Calithera Biosciences (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Fortress Biotech (Inst), Karyopharm Therapeutics (Inst), Oxford BioTherapeutics (Inst), Astex Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Adaptimmune (Inst), SpringWorks Therapeutics (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Companion diagnostics for CD4 inhibitors (Inst), patent granted to develop a new technology called PNAs for cancer therapyTravel, Accommodations, Expenses: Array BioPharma, EpizymeMatthew InghamConsulting or Advisory Role: Daiichi Sankyo, Xencor, Apexigen, Epizyme, Caris Life SciencesResearch Funding: Apexigen (Inst), Mirati Therapeutics (Inst), PTC Therapeutics (Inst), APICESTravel, Accommodations, Expenses: GenentechNo other potential conflicts of interest were reported.